依類型篩選 全部顯示 頁面 解決方案 專業服務 報告 新聞 Webinars 活動 地點 問與答 案例研究 白皮書 Filter By 任何 頁面 解決方案 專業服務 報告 新聞 Webinars 活動 地點 問與答 案例研究 白皮書 2017/10/16 新聞 The Road Less Travelled – Navigation through the do’s and don’ts of running Oncology studies in… The Road Less Travelled – Navigation through the do’s and don’ts of running Oncology studies in A 報告 2020/7/15 Webinar Advancing oncology trials in Asia-Pacific Arsalan Arif: 觀看 2022/7/21 Webinar Evolution of cell & gene therapy in China: the case for universal CAR-T JIE CHEN CHIEF MEDICAL OFFICER, BIOHENG 觀看 2022/12/21 新聞 Novotech Sponsors “The Next Big Thing in Cancer Care” Webinar - CAR-T, Precision Oncology, AI and… Novotech, the Asia Pacific centered biotech specialist CRO, presents “The Next Big Thing in Cance 報告 2022/10/7 新聞 Featured in the endpoints news- the factors driving a rapid evolution of gene & cell therapy and… APAC is the fast growing region globally for cell & gene therapy trials representing 報告 2019/11/15 新聞 Asia-Pacific shows higher patient recruitment rates for Oncology clinical trials Biotechnology companies are facing tremendous challenges around patient recruitment, lengthy time 報告 2019/11/20 新聞 Novotech discusses biotechnology CRO services at leadership meeting in Malaysia Novotech is a full service CRO, offering CRO services across all the Asia-Pacific region with ope 報告 2017/9/29 新聞 Webinar - Navigating Oncology Trials in Asia: How a Regional CRO can Deliver on a Global Project Almost half of these occur in Asia with almost one quarter of the global burden in China. 報告 2023/1/23 Webinar The Next Big Thing in Cancer Care Dr. Peter Paul Yu: 觀看 2017/10/5 新聞 Novotech Awarded Asia-Pacific Biotech CRO of the Year - Announced at ASCO The announcement was made at the ASCO Annual Meeting (May 31 - June 4, 2019 McCormick Place, Chi 報告 2020/1/6 新聞 Immuno-Oncology clinical trial landscape in Asia-Pacific A growing number of biotechnology companies are looking at Asia and Australia to run their 報告 2021/2/11 新聞 Celebrating International Day for Women and Girls in Science 2021 Thursday 11 February 2021 報告 2022/5/30 Webinar 基於早期腫瘤試驗的 Go/No Go 決策 小組專題討論 李進博士，上海市東方醫院 嚴立博士，騰盛博藥 (Brii Biosciences) 醫學長、美中抗癌協會 (USCACA) 常務董事 觀看 Greater China At more than 1.4 billion people, China is the world’s most populated country, with an increasing 2021/3/24 Webinar 亞太地區：加速您臨床試驗計劃的解決方案 Ms Norial: Hi everyone and thank you for joining our Novotech presentation on Asia Pacific 觀看 2020/9/25 Webinar Accelerating Clinical Trials in Australia and Asia – Presented by Steven Roan at OCT USA Hello, good morning, good afternoon, good evening. Thank you very much for taking the time to join the pre 觀看 2022/6/2 新聞 Novotech 贊助 ASCO 中國峰會前中美早期腫瘤試驗和監管策略專家組 澳大利亞悉尼 - Novotech 是亞太地區領先的生物技術專家 CRO，最近將其服務擴展到美國，在 2022 年 ASCO 前中國峰會上贊助了專家小組，匯集了 報告 2023/4/28 報告 卵巢癌 – 全球臨床試驗概況 - 聚焦亞太地區 2020 年，亞洲佔全球卵巢癌發病病例的一半以上，其中大部分的病例來自中國和印度。 下載 2021/12/17 報告 Gastric cancer Clinical trial landscape Asia-pacific Nearly 75% of the new gastric cancer cases in the world are concentrated in Asia, with China showing the highest incidence and mortality. 下載 2022/9/2 新聞 根據 GlobalData 的新報告，亞太地區吸引 50% 的全球臨床試驗 Novotech 是亞太地區首屈一指的生物科技專業 CRO 公司，已在一份標題為 《亞太地區的臨床試驗進展》 的報告中，公開發布了新的市場資料。 報告 2023/6/26 報告 肝癌 – 全球臨床試驗概況 - 聚焦亞太地區 2020 年，亞洲佔全球肝癌發病率病例的 70% 以上，其中以中國占大多數。預計 2020 年至 2040 年間，每年全球疾病發病率將增加 55.0%。 下載 2022/5/24 報告 Renal Cell Carcinoma Owing to its large population base, Asia accounts for over 35% of the estimated global incidence of Renal cell carcinoma, with China, Japan, and India collectively contributing to over a quarter of 下載 2023/4/6 報告 乳癌 - 全球臨床試驗概概況 - 以亞太地區為主。 亞洲約佔 2020 年全球乳癌病例的 45%，多數病例分布在中國大陸、印度和日本 下載 2019/8/25 Case Study 挽救試驗和腫瘤學 CRO 服務當地技術使關鍵的乳癌試驗重回正軌 背景介紹 當一項全球乳癌試驗的招募工作正面臨延滯時，Novotech 被聘為亞太地區 CRO，以幫助該專案重回正軌。 了解更多 2021/11/29 報告 Colorectal cancer clinical trials landscape asia pacific The incidence of colorectal cancer cases is rapidly growing in Asia-Pacific and the region now accounts for more than half of all new cases diagnosed globally. 下載 2022/6/6 新聞 Novotech 助力 Endpoints ASCO 2022 年專家小組加速中國腫瘤臨床試驗進程 雪梨 - Novotech 是亞太地區首屈一指的生物科技專業 CRO，近期進駐美國拓展其服務範圍，助力 Endpoints ASCO 2022 年專家小組，「加速中國和美國臨床試 報告 2023/6/2 白皮書 溶瘤病毒治療-全球臨床試驗綜覽-聚焦亞太地區 過去五年內，亞太地區的溶瘤病毒治療試驗數量持續以最快速的方式增加，到了 2022 年，該地區已擁有全球溶瘤病毒治療試驗數量的 40 % 以上。 下載 2022/2/24 報告 Small cell lung cancer Each year, there are over 300,000 new cases of Small Cell Lung Cancer globally, with Asia accounting for nearly 60% of the cases. 下載 2023/3/14 新聞 Novotech 發布多特異性單株抗體全球臨床試驗概況報告 新加坡 - 以亞太地區為中心的頂尖生物技術 CRO Novotech 發佈了一份關於全球多特異性單株抗體 (Mabs) 臨床試驗現狀的新報告，包括對亞太地區、歐 報告 2021/2/15 報告 AML Landscape in Asia-Pacific AML is the most common form of leukemia in adults, accounting for approximately a third of all leukemia cases worldwide. 下載 2021/10/12 報告 Clinical trial landscape of Liver cancer in asia pacific According to the Globocan 2020 report, liver cancer is the fourth most frequent cancer in Asia, with the region accounting for over 70% of all new liver cancer cases worldwide. 下載 2022/7/27 報告 Solid tumors - Asia Pacific – Clinical trial Landscape There were over 8.2 million new cases and over 5 million deaths due to solid cancers in Asia, with the region accounting for half of the new cancer cases and 60% of the world’s deaths in 2020. 下載 2023/5/26 新聞 Novotech 贊助 2023 年 ASCO 年會：與世易醫健 (eChina Health) 聯合舉辦腫瘤峰會，並與 Endpoints 聯合召開加速藥物開發的專家小組討論會 美國伊利諾州芝加哥 - Novotech 是亞太地區領先的生物科技受託研究機構 (CRO)，為美國臨床腫瘤學會 (ASCO) 的兩項以腫瘤學為重點的專家活動提供 報告 2022/1/21 報告 Thyroid cancer Asia accounted for almost 60% of the global incidence, mortality and five-year prevalence in 2020, with the highest incidence rates found in Australia and Eastern Asia for both sexes. 下載 2023/3/3 報告 急性骨髓性白血病 (AML) - 全球臨床試驗概況 - 著重於亞太地區。 2020 年亞太地區約有 46,000 AML 病例，其中中國、印度和日本佔全球 40% 的病例。 下載 2023/8/28 報告 膽囊癌：全球臨床試驗概況 惡性腫瘤細胞在膽囊黏膜層中增生並向外擴展，就會逐漸形成膽囊癌。最盛行的膽管癌佔全世界案例的 80%-95%，在胃腸道癌症排名第六。全球統計數據顯示女性比男性更容易罹患此疾病，2020 年記錄超過一百萬例新案例。值得注意的是，亞洲佔大多數案例和死亡人數，而歐美的案例相對較少。 下載 2022/6/7 Webinar 加速中國和美國臨床試驗開發 Novotech 擁有兩國經驗豐富的臨床團隊，即將分享真實世界的成功策略給全球正在進行臨床開發計劃的生物科技公司。 觀看 2023/5/2 白皮書 RNA 療法 – 全球臨床試驗概況 – 聚焦亞太地區 與世界其他地區相比，亞太地區在 RNA 療法試驗方面擁有最快的五年增長率，該地區在 2022 年 貢獻了全球三分之一以上的 RNA 試驗。 下載 2021/12/17 報告 Pancreatic cancer Clinical trials landscape Asia pacific The incidence of pancreatic cancer is rising in Asia-Pacific, with the region accounting for about half of new cases in 2020. 下載 2022/9/29 報告 膽管癌 (Cholangiocarcinoma) 亞太地區 – 臨床 試驗狀況 與世界各地相比，亞洲地區膽管癌盛行率顯著較 高，其中以中國、南韓、泰國與台灣的發生率最 高。 收購及整合長期經營的全方位服務 CRO 合作夥 伴之後，Novotech 現在能為全美國提供服務。 下載 2023/9/5 白皮書 罕見疾病 - 全球臨床試驗概況 探索罕見疾病全球臨床試驗概況：揭開挑戰、趨勢和有前景的進展 下載 2022/5/26 白皮書 Next Generation Sequencing NGS profiling improves patient outcomes while also lowering treatment costs and time to diagnosis for cancer patients 下載 2023/4/27 報告 黑色素瘤 - 全球臨床試驗概況 - 聚焦亞太地區 亞洲在 2020 年產生了近 24,000 例黑色素瘤病例，以澳洲和紐西蘭的發病率佔世界首位。 下載 2021/11/29 報告 Lung cancer (nsclc) clinical trials landscape asia pacific In Asia, lung cancer ranks as the most prevalent cancer and the primary cause of mortality, with the region accounting for almost 60% of the global incidence of lung cancer. 下載 2022/9/5 新聞 NOVOTECH 參加 2022 年歐洲腫瘤學學會大會 (ESMO CONGRESS) — 新資料顯示亞太地區的腫瘤試驗成長率達 100% 在 #409 號展位與團隊會面 報告 2023/6/14 Webinar Endpoints 在 2023 年美國臨床腫瘤學會年會 (ASCO23)：如何從起跑線上加速新型和先進腫瘤療法的發展 Vishal Navani 腫瘤科醫師、教授 觀看 2022/3/31 報告 Triple negative breast Cancer With a high population density and over 45% of the global breast cancer incidence, Asia is expected to account for more than half of all TNBC cases, with a large TNBC patient pool, particularly in 下載 2023/4/5 報告 攝護腺癌 - 全球臨床試驗概況 - 以亞太地區為主 2020 年，亞洲在全世界攝護腺癌發病例中佔了四分之一以上，而中國和日本兩國在此地區共有超過 220,000 起新發病例。 下載 2019/8/27 Case Study 尋找腫瘤學 CRO 服務的生物科技公司。法規與招募上的專業知識加快了腫瘤臨床試驗的時間表。 背景介紹 當南韓腫瘤生物科技公司 PharmAbcine 在國內成功完成了治療轉移性/頑固性實質固態瘤的第 I 期試驗時，他們渴望進展到第 II 期。 了解更多 2021/11/3 報告 Esophageal cancer – Clinical trials landscape – Asia pacific In Asia, EC is the sixth most common cancer, with the region constituting almost 80% of the new EC cases globally. The highest standardized incidence rate has been observed in East Asia. 下載 2022/8/5 白皮書 Immuno-oncology – Asia pacific – clinical Trial landscape Asia Pacific has shown significant increase in Immuno-oncology trials between 2017 and 2021 and contributes to more than a third of the global clinical development of Immune-oncology drugs. 下載 2023/5/26 報告 非何杰金氏淋巴瘤 – 全球臨床試驗概況 - 聚焦於亞太地區 2020 年，亞洲佔全球非何杰金氏淋巴瘤 40% 以上的發病率，其中又以中國佔最多數 下載 2022/1/21 報告 Bladder cancer Asia accounted for over a third of the global bladder cancer incidence with over 200,00 newly diagnosed cases, with China having a higher prevalence of bladder cancer in 2020. 下載 2023/3/2 白皮書 多專一性單株抗體 - 全球臨床試驗概覽 - 著重於亞太地區 自 2018 年以來，亞太地區是多專一性單株抗體試驗成長最迅速的地區，試驗數量占全球試驗 40% 以上，比例相對高出美國及歐洲。 下載 專業服務 腫瘤學 CRO 服務 生技企業公司在招募和留住參加者、冗長時程和高昂成本等方面，面臨日益嚴峻的挑戰。 2021/9/17 報告 Clinical trial landscape of endometrial cancer in asia-pacific In 2020, Globocan reported over 400,000 new corpus uteri cases, with Asia accounting for about 40% of these new cases. 下載 2022/7/13 報告 Multiple myeloma - Asia pacific – clinical Trial landscape Multiple myeloma cases are increasing in Asia, with the region currently contributing to more than 35% of the projected global incidence, with China, India, and Japan comprising more than a quarter 下載 2023/6/2-6 活動 美國臨床腫瘤學會 (ASCO) 年會，（實體會議）美國芝加哥 了解更多 2021/12/17 報告 Cervical cancer Asia pacific Clinical trial landscape Asia accounts for almost 60% of the global incidence of cervical cancer, with India and China together contributing to more than a third of all cases and deaths. 下載 2022/11/22 新聞 Oncoshot and Novotech Partner to Offer Cancer Data Insights SINGAPORE, October 2022 /PRNewswire/ -- Oncoshot and internationally recognised contract research 報告 2023/9/1 報告 鼻咽癌：全球臨床試驗概況 鼻咽癌是源於鼻咽上皮最常見的癌症，通常是未分化癌。此癌症主要發現於亞洲和非洲。非角化型鼻咽癌佔所有鼻咽癌案例大約 50%。在新式治療時代期間，全世界鼻咽癌 5 年存活率是 40-70%。2020 年，超過 130,000 個鼻咽癌病例對全球造成衝擊，使得鼻咽癌成為世界上第 23 常見癌症。男性比女性更可能發生鼻咽癌，男女比例為 2-3 比 1。 下載 2021/11/9 新聞 Novotech Platinum Sponsor at ChinaTrials13 Summit Shanghai 2021 Sydney - Novotech, a leading biotech specialist CRO in the Asia-Pacific region, 報告 Philippines The Philippines is the world’s 12th most populous country, with a growing, newly industrialized e Proposals, Budgets and Contracts Graduate Program January 2023 Intake - Malaysia 2009/8/31 新聞 NOVOTECH CRO ATTRACTS INVESTMENT FOR ASIA CLINICAL TRIAL EXPANSION NOVOTECH CRO ATTRACTS INVESTMENT FOR ASIA CLINICAL TRIAL EXPANSION 報告 Clinical Research Associate (CRA) Essentials Program JANUARY 2022 INTAKE – AUSTRALIA AND NEW ZEALAND We are internationally recognized as a leading regional ful 2013/5/31 新聞 Novotech appointed Contract Research Organisation for upcoming Phase 1b/2 study of HER-Vaxx in… Imugene’s clinical review for HER-Vaxx is now complete HER-Vaxx Phase 1b/2 in gast 報告 2020/4/24 新聞 Biotechnology Companies Turning to Asia-Pacific for Clinical Trials During North America Slowdown. Biotechnology sponsors are attracted to the region because sites ha 報告 South Korea South Korea has a population of 51 million, offers world-class infrastructure and is fast becomin 2016/1/8 新聞 Novotech initiates cancer trials in Australia and New Zealand for Oncomed Pharmaceuticals Novotech initiates cancer trials in Australia and New Zealand for Oncomed Pharmaceuticals 報告 Associate Project Manager Program JANUARY 2022 INTAKE – AUSTRALIA 2011/7/5 新聞 NOVOGEN ENGAGES CONTRACT RESEARCH ORGANISATION TO CONDUCT CANTRIXIL PHASE 1 CLINICAL TRIAL Sydney, November 24, 2015 - US-Australian drug discovery company, Novogen Limited (ASX:NRT: NASDA 報告 2020/1/13 新聞 Asia-Pacific has record year for clinical trials according to Novotech San Francisco, CA – Novotech the largest biotech CRO in the Asia-Pacific said th 報告 2011/6/15 新聞 SureClinical eTMF Cloud Selected by Novotech to automate and accelerate clinical operations… SureClinical eTMF Cloud Selected by Novotech to automate an 報告 New Zealand Importantly, New Zealand also offer alternative recruitment potential to northern hemisphere seas 2022/10/25 白皮書 The China Biotech Landscape – Opportunities in China and the Path to USFDA Approval Global biopharma companies are looking to capitalize on value creation across different geographic regions through ut 下載 2019/1/29 新聞 Novotech Update: South Korea to cover standard of care for patients participating in clinical trials In a recent update, South Korea’s National Health Insurance Program outlined plans to also cover 報告 2022/10/27 常見問答 Contract Research Organisations: Market and Trends The Contract Research Organisation (CRO) industry is constantly changing and growing due to various key factors like a growing healthcare sector, research funds, a growing patient population worldw 了解更多 2020/6/15 新聞 Novotech Partners with South Korea’s 1,300-bed Pusan National University Hospital The leading Asia-Pacific biotech 報告 2020/7/29 常見問答 How CRO Companies Work? - A Basic Overview It’s quite common for pharmaceutical and biotechnology companies introducing new drugs and treatment to outsource trials of new medication or procedures to CRO Companies. 了解更多 2014/5/10 新聞 Novotech announces four country Asia expansion at AusBiotech 2009 October 27, 2009 報告 Solution Site Management Organization (SMO) 2019/12/10 新聞 Novotech CRO sees changing landscape in Hemato-Oncology at ASH 2019 Novotech, the Asia-Pacific CRO, attends the American Society of Hematology conference in Orla 報告 2020/4/9 新聞 Novotech selected for new COVID-19 Clinical Trial in Asia-Pacific Novotech has been engag 報告 2020/8/12 Webinar Running First-in-human and Vaccines Studies in Australia Arsalan Arif: Hi everyone and welcome to our webinar. 觀看 2019/11/22 新聞 Novotech’s Clinical Network Services wins GENE Awards for Industry excellence in biotech drug… Clinical Network Services, a subsidiary of Novotech, the Asia-Pacific CRO, was awarded a prestigi 報告 2021/10/21 Webinar 透過虛擬試驗解決方案來提升亞太地區的臨床試驗效率 Arsalan Arif: Hi everyone. 觀看 載入更多
